Posters

Application of ultrahigh resolution OCT for assessment of Schlemm’s canal microstructure

Poster Details

First Author: S.Sapeta POLAND

Co Author(s): G. Sunaric Megevand   L. Schmetterer   R. Werkmeister              

Abstract Details

Purpose:

To investigate the capability of ultrahigh-resolution OCT for imaging of Schlemm’s canal microstructure and providing an insight into aqueous outflow system (AOS).

Setting:

(1) Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Austria, (2) Singapore Eye Research Institute (SERI), Singapore National Eye Center, Singapore, (3) Department of Ophthalmology, University Clinical Center, Medical University of Silesia, Katowice, Poland, (4) Clinical Research Center Rothschild Foundation, Geneva, Switzerland, (5) Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore

Methods:

SC cross-sectional area was measured using the UHR-SDOCT, providing a theoretical axial resolution of 1.2 µm in tissue, in 10 healthy volunteers during 2 conditions: before and after topical instillation of 2% Pilocarpine.

Results:

10 healthy volunteers (5 female,5 male; average age of 32.1 ± 11.0 years) were included in the study. Following instillation of one drop pilocarpine, mean IOP in the study eye decreased from 13.3 ± 2.9 mmHg to 11.5 ± 3.1 mmHg (p = 0.03). The mean Schlemm’s canal lumen area (SCLA) of all subjects at baseline was 3620 ± 589 µm2 nasally and 4075 ± 335 µm2 temporally. After administration of pilocarpine, SCLA increased to 7772 ± 994 µm2 (p = 0.002) on the nasal and to 7760 ± 857 µm2 on the temporal side (p = 0.002), respectively.

Conclusions:

UHR-OCT allows for detailed visualization of AOS morphology and precise measurement of SCLA with resolution, that is not provided in conventional OCT. This system is a promising technique which could allow for selection of better therapy options for glaucoma patients, as well as in predicting outcomes of pharmacological, laser and surgical treatment.

Financial Disclosure:

None